Randhawa Simrat 4
4 · Dianthus Therapeutics, Inc. /DE/ · Filed Jun 2, 2026
Research Summary
AI-generated summary of this filing
Dianthus (DNTH) EVP Simrat Randhawa Exercises Options and Sells Shares
What Happened
Simrat Randhawa, EVP and Head of R&D at Dianthus Therapeutics (DNTH), exercised a total of 26,530 option-based derivative awards and immediately sold the same 26,530 shares in open-market transactions on June 1, 2026. The exercises cost approximately $500,205 in aggregate (breakdown below) and the open-market sales generated about $2,404,077 in gross proceeds. These transactions were executed pursuant to a Rule 10b5-1 trading plan.
Key Details
- Transaction date: June 1, 2026; Form 4 filed June 2, 2026 (timely).
- Options exercised (acquired): 26,530 shares total
- 3,998 @ $8.44 = $33,743
- 6,908 @ $17.88 = $123,515
- 6,249 @ $21.77 = $136,041
- 9,375 @ $22.07 = $206,906
- Total exercise cost ≈ $500,205
- Open-market sales (disposed): 26,530 shares total for ≈ $2,404,077
- 5,428 shares — weighted avg $89.72 (range $89.17–$90.16) — $487,000 (F2)
- 16,943 shares — weighted avg $90.72 (range $90.17–$91.15) — $1,537,069 (F3)
- 4,159 shares — weighted avg $91.37 (range $91.17–$91.96) — $380,008 (F4)
- Filing notes: Transaction executed under a Rule 10b5-1 trading plan (F1). Several footnotes (F5–F8) describe vesting schedules for the related option awards. The filing does not specify shares owned after the transactions in the provided summary.
- Transaction codes: M = option exercise/conversion; S = open-market sale.
Context
This was an exercise of stock options followed by immediate open-market sales — effectively a cashless exercise where the exercised shares were sold. The use of a Rule 10b5-1 plan means the sales were pre-specified and likely automated under plan terms; such sales are often routine and do not by themselves indicate a view about the company’s prospects. All figures above are from the Form 4; motivations are not stated.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-06-01$8.44/sh+3,998$33,743→ 7,998 total - Exercise/Conversion
Common Stock
[F1]2026-06-01$17.88/sh+6,908$123,515→ 14,906 total - Exercise/Conversion
Common Stock
[F1]2026-06-01$21.77/sh+6,249$136,041→ 21,155 total - Exercise/Conversion
Common Stock
[F1]2026-06-01$22.07/sh+9,375$206,906→ 30,530 total - Sale
Common Stock
[F1][F2]2026-06-01$89.72/sh−5,428$487,000→ 25,102 total - Sale
Common Stock
[F1][F3]2026-06-01$90.72/sh−16,943$1,537,069→ 8,159 total - Sale
Common Stock
[F1][F4]2026-06-01$91.37/sh−4,159$380,008→ 4,000 total - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F5]2026-06-01−3,998→ 0 totalExercise: $8.44Exp: 2032-06-06→ Common Stock (3,998 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F6]2026-06-01−6,908→ 64,276 totalExercise: $17.88Exp: 2034-01-23→ Common Stock (6,908 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F7]2026-06-01−6,249→ 47,925 totalExercise: $21.77Exp: 2034-05-22→ Common Stock (6,249 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F8]2026-06-01−9,375→ 96,875 totalExercise: $22.07Exp: 2035-02-03→ Common Stock (9,375 underlying)
Footnotes (8)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025.
- [F2]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.17 to $90.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.17 to $91.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.17 to $91.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F5]The shares of common stock underlying this stock option award vested as to 25% of the shares on April 25, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
- [F6]The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
- [F7]The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
- [F8]The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date.